Results

Total Results: 884 records

Showing results for "end stage renal".

  1. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-262-pharmacotherapy-alcohol-disposition-comments.pdf
    November 07, 2023 - Page 32, line 45: Missing “placebo” from the end of the first sentence. … Expert #4 ES Page v line 49 As a clinician I do not find contraindication to acamprosate (severe renal … major decision maker in this section, or if it stays in, specify that the contraindication is severe renal … should be careful to respect contraindications of each individual medication (for acamprosate, severe renal … Public Comment #3 (APA) Introduction p. 4 table disulfiram Suggest changing "at the acetaldehyde stage
  2. www.ahrq.gov/hai/cauti-tools/guides/implguide-pt3.html
    October 01, 2015 - Assistance with healing of stage III or IV perineal and sacral wounds in incontinent patients —This is … For example, indwelling urinary catheters can be appropriate for stage III, IV, or unstageable pressure … Hospice/comfort/palliative care —This is an acceptable indication for catheter use in end-of-life care … urine output as part of routine care when admitted for certain conditions such as heart failure or renal … An exception would be for patients who are receiving end-of-life or palliative care and in whom a catheter
  3. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/49843/psn-pdf
    October 01, 2018 - In the end, clinicians realized that the patient had initially been misdiagnosed with sepsis and that … organ dysfunction, such as hypotension, elevated lactate, respiratory failure, altered mental status, renal … the patient described had laboratory evidence of inflammation (elevated white blood cell count) and end-organ … When patients present with circulatory shock or signs of end-organ dysfunction, empiric antibiotics
  4. effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-2006_appendixes.pdf
    January 01, 2006 - in 2-3 doses; Extended- release, 100-200 mg/day RA: Delayed- release, 100-200 mg/day in 3- 4 Renal … impairment(CrCl >25 mL/min) max 150 mg/day; Moderate renal impairment (CrCl l<25 mL/min) max 100 … (Give numbers at each stage of attrition.) … : No SS difference b/t lumiracoxib and NSAIDs for renal endpoint or serious liver AEs. … update 9/16/02 Pain reduction 2 placebo controlled trials provided pain intensity at baseline and end
  5. www.ahrq.gov/patient-safety/settings/esrd/resource/cultureofsafety.html
    January 01, 2015 - Creating a Culture of Safety ESRD Toolkit The Creating a Culture of Safety module of the ESRD Toolkit discusses the importance of a comprehensive, unit-based approach to safety and its impact on improving patient care and reducing harm in dialysis centers. Presentation Slides ( PPTX, 20 M B) Facilitator …
  6. www.ahrq.gov/patient-safety/settings/esrd/resource/checklist.html
    January 01, 2015 - Using Checklists and Audit Tools ESRD Toolkit The Using Checklists and Audit Tools module of the ESRD Toolkit explains the importance of using data in the quality assurance and performance improvement process, and explains how implementing checklists and audit tools aligns with the principles of safe design. …
  7. hcup-us.ahrq.gov/db/nation/nrd/NRD_Introduction_2013.jsp
    January 01, 2013 - Medicare patients younger than 65 include people who are disabled or who have been diagnosed with end-stagerenal disease or amyotrophic lateral sclerosis (ALS). … software packages that perform calculations for numerous statistics arising from the stratified, single-stage … Medicare patients under the age of 65 include people who are disabled or who have been diagnosed with end-stagerenal disease or amyotrophic lateral sclerosis (ALS).
  8. effectivehealthcare.ahrq.gov/sites/default/files/topic-refinement.ppt
    March 01, 2010 - What is the risk of renal dysfunction, hyperkalemia, cough, and angioedema associated with the use of … The second question is, “What is the risk of renal dysfunction, hyperkalemia, cough, and angioedema associated … Many surrogate/intermediate end points have not been adequately validated. … Just because there is enough information to pool a myriad of intermediate end points does not mean that … This completes the topic refinement project and sets the stage for the next phase, in which the key questions
  9. www.uspreventiveservicestaskforce.org/home/getfilebytoken/We5A-uCMvX5qYeFukGgqks
    March 01, 2004 - We excluded studies of pregnant patients; children; and patients with occupational exposures, end-stage … Clinical outcomes that we evaluated were mortality, end-stage liver disease, cirrhosis, and hepatocellular … We excluded studies that focused only on patients with end-stage liver disease, cirrhosis, or hepatocellular … undergone transplantation were excluded, as were studies of pregnant patients, children, or those with end-stagerenal disease or HIV infection.
  10. www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/hepatitis-c-virus-infection-screening-2004
    March 08, 2004 - We excluded studies of pregnant patients; children; and patients with occupational exposures, end-stage … Clinical outcomes that we evaluated were mortality, end-stage liver disease, cirrhosis, and hepatocellular … We excluded studies that focused only on patients with end-stage liver disease, cirrhosis, or hepatocellular … undergone transplantation were excluded, as were studies of pregnant patients, children, or those with end-stagerenal disease or HIV infection.
  11. www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary43/prostate-cancer-screening-2012
    October 07, 2011 - What are the harms of treatment of early-stage or screening-detected prostate cancer? … Surveillance, Epidemiology, and End Results (SEER) program ( n =25,900) of men 65 to 80 years of age … comorbid conditions (diabetes, cardiovascular disease, respiratory disease, gastrointestinal disease, renal … 1: 29%  Stage 2: 40%  Stage 3: 31%  PSA < 10 µg/L: 22% PSA 11–29 µg/L: 28% PSA > 30 µg/L: 23% PSA unknown … prostate-specific antigen; RCT = randomized, controlled trial; SEER = Surveillance, Epidemiology, and End
  12. digital.ahrq.gov/sites/default/files/docs/citation/r13hs024833-gill-final-report-2017.pdf
    January 01, 2017 - Results: By the end of Day 2, the group of stakeholder representatives and subject matter experts produced … These talks set the stage for development of guidelines that address the needs of these priority populations … reality include but are not limited to (i) the training of health professionals (e.g., percutaneous renal … If recognition of biases and defective perceptions in VR does not occur, we could end up increasing
  13. psnet.ahrq.gov/perspective/conversation-sharon-k-inouye-md-mph
    December 01, 2012 - tried to get them to share what they were using with me because I really viewed that as a means to an end … delirium, some of them say things like delirium following alcohol withdrawal, or delirium following renal … They're a little hyponatremic, going into renal failure, and on medications that maybe the doctor has … brain function [ 5 ]), it is worth thinking about delirium as an "acute brain injury" similar to other end-organ … As with these other important end-organ injuries, delirium is a clinical event for which prevention and
  14. www.uspreventiveservicestaskforce.org/home/getfilebytoken/nmcMhEwWT9BncBBBQQN6Uf
    December 01, 2015 - years, with exponential distribution using DCIS incidence data from the Surveillance, Epidemiology and End … On the other end of the spectrum, the model allows for another subset of tumors to be “aggressive” by … years to capture lifetime reductions in breast cancer mortality occurring years after the start (and end … Surveillance, Epidemiology and End Results Program (SEER): SEER*Stat Software. … )vascular disease; paralysis; diabetes 12% 13 Severe AIDS; mild or severe liver disease; chronic renal
  15. www.uspreventiveservicestaskforce.org/Home/GetFile/1/16255/collabmodelingbc/pdf
    December 01, 2015 - years, with exponential distribution using DCIS incidence data from the Surveillance, Epidemiology and End … On the other end of the spectrum, the model allows for another subset of tumors to be “aggressive” by … years to capture lifetime reductions in breast cancer mortality occurring years after the start (and end … Surveillance, Epidemiology and End Results Program (SEER): SEER*Stat Software. … )vascular disease; paralysis; diabetes 12% 13 Severe AIDS; mild or severe liver disease; chronic renal
  16. digital.ahrq.gov/sites/default/files/docs/page/findings-and-lessons-from-clinical-decision-support-demonstration-projects.pdf
    June 01, 2014 - Most directly, one of the Stage 1 objectives is for providers to “implement one clinical decision support … CDS-related objectives for Stage 1 meaningful use include the following: • Capturing clinical data … specialty or high clinical priority along with the ability to track compliance with that rule.3 Stage … could lead to conflicting clinical recommendations (e.g., a patient with diabetes, heart failure, and renal … Although the use of CDS is a core measure for all stages, meaningful use Stage 3 is expected to have
  17. cds.ahrq.gov/sites/default/files/cds/artifact/26/Implementation%20Guide_USPSTF%20Aspirin%20Therapy%20for%20the%20Prevention%20of%20CVD%20and%20CRC_Final.docx
    October 01, 2017 - Patient has end-stage renal disease. e. Patient is on another anticoagulant. f. … Figure 1: CDS Artifact Maturity Process To continue the maturation of this artifact to the structured stage … Diagnosis of GI bleed OR Diagnosis of GI ulcers OR Diagnosis of bleeding disorders OR Diagnosis of renal
  18. digital.ahrq.gov/sites/default/files/docs/citation/ereferralimplementationreportfinal.pdf
    February 01, 2012 - next patient. 64.4 percent (203) complete the electronic referral AFTER patient visits, e.g., at the end … think some people have been less eager to adopt it because it takes a little bit longer on the front end … It used to just be every referral got at the end of the line. … The design team considered workflow at the system development stage. … End Points. An end point is the event by which a process is deemed completed.
  19. effectivehealthcare.ahrq.gov/sites/default/files/pdf/hepatitis-c-treatment-adherence_research-protocol.pdf
    September 13, 2011 - population includes patients for whom treatment is contraindicated:  Pregnant women  Patients with renal … We will code the reason any articles, at the stage of the full-text review, are not included in the … Studies at the abstract and full-review stage will be managed with Reference Manager so that we can … Because of their role as end-users, individuals are invited to serve as Key Informants and those who … population include patients for whom treatment is contraindicated:  Pregnant women  Patients with renal
  20. effectivehealthcare.ahrq.gov/sites/default/files/pdf/horizon-scan_research-2015.pdf
    January 01, 2015 - payers have also broadened the eligibility for treatment to include infected individuals with earlier stage … Lymphomas Intranasal Oxytocin for Social Dysfunction in Autism Spectrum Disorders Catheter-Based Renal … some third-party payers is to treat only those patients in advanced 10 stages of infection (stage … When added to standard intraoperative assessment during lumpectomy for early stage breast cancer, MarginProbe … Care System for Preserving Donor Lungs A double-lung transplant is a last resort for patients with end-stage